Drug-induced lung disease.
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000925:Anticoagulants / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D001761:Bleomycin / Q000009:adverse effects; D002066:Busulfan / Q000009:adverse effects; D002747:Chlorpropamide / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D003932:Heroin / Q000009:adverse effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects; D006976:Hypertension, Pulmonary / Q000139:chemically induced; D001239:Inhalation; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008055:Lipids / Q000009:adverse effects; D008168:Lung / Q000473:pathology; D008171:Lung Diseases / Q000139:chemically induced* / Q000473:pathology; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008784:Methysergide / Q000009:adverse effects; D009582:Nitrofurantoin / Q000009:adverse effects; D010672:Phenytoin / Q000009:adverse effects; D011654:Pulmonary Edema / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D000959:Antihypertensive Agents; D008055:Lipids; D006852:Hydrochlorothiazide; D001761:Bleomycin; D010672:Phenytoin; D003932:Heroin; D003520:Cyclophosphamide; D009582:Nitrofurantoin; D002066:Busulfan; D002747:Chlorpropamide; D008784:Methysergide; D008727:Methotrexate